Company intelligence / Profile preview

Unitrans

Silver Spring, Maryland, USAunitrans.ucdavis.edu ↗

Ownership: Private
Employees: ~900
Development stage: Other

Overview

United Therapeutics has several FDA-approved therapies for PAH, including Remodulin, Tyvaso, Orenitram, Adcirca, and Unituxin. Its inhaled treprostinil program is advancing into new indications such as idiopathic pulmonary fibrosis. The company has achieved major milestones in xenotransplantation with successful preclinical trials and first-in-human procedures using bioengineered organs.

Therapeutic areas: Rare DiseasesPulmonologyCardiovascularOncology
Modalities: Small moleculeMonoclonal antibodyCell-based therapyBiologicRecombinant protein (for organ engineering)Inhaled therapies
Industry: Biotech

Partnerships

Eli Lilly and CompanyDEKA Research & Development Corp.MannKind CorporationNational Cancer Institute

Beyond the preview

Go deeper on Unitrans.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Unitrans.

Explore the full profile